Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1921MR)

This product GTTS-WQ1921MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species synthetic construct
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1921MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13178MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ8088MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ10533MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ5908MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ1003MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ6914MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ3431MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ363MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW